The problem with plasma has always been the freezer. It is the part of blood that carries the clotting factors, the thing a bleeding patient needs most and fastest, and it has to be kept frozen and then thawed before anyone can use it. Ambulances do not have freezers. Neither do most remote clinics, disaster tents, or forward positions in a war.
On Wednesday the FDA licensed Ezplaz, the first freeze-dried plasma product in the United States. It stores between 2 and 25 degrees Celsius, ordinary room temperature, for twelve months, and reconstitutes in roughly one to two and a half minutes. [1] The kit is self-contained: the plasma unit, sterile water, a transfer set, a transfusion set, derived from a single unit of fresh frozen plasma. [2] AABB, the transfusion medicine body, describes it as suitable for "austere settings, including combat zones, remote areas and disaster response." [2]
Read the label carefully, because the indication is narrower than the excitement: it is approved for transfusion in adults when plasma is required and other plasma products are not available. [1] That conditional is the whole point rather than a limitation. This is the plasma for when there is no plasma.
The timeline is its own story. The product was developed under a Cooperative Research and Development Agreement with the Defense Health Agency, initiated in April 2014. [1] Twelve years from that agreement to a license. Teleflex's Jake Newman describes the destination as "air and road ambulances, in the hospital, and on the battlefield." [1]
The month's other first asks to be read with equal care. On July 16, the FDA approved Lipfendra, enlicitide, the first once-daily oral PCSK9 inhibitor: a 20 milligram tablet replacing a class of drugs that until now required injection. In two trials, it cut LDL cholesterol by 56 percent and 59 percent against placebo at 24 weeks. [3] For people who need that magnitude of lowering and cannot manage injections, a pill is a genuine change in what is possible.
Here is the honest caveat, and it comes from Merck itself: "It is not yet known if LIPFENDRA can reduce the risk of cardiovascular morbidity and mortality." [3] The approval rests on LDL reduction, a surrogate marker. Whether the pill actually prevents heart attacks and strokes is being tested right now in CORALreef Outcomes, a trial of 14,550 people that began in October 2023 and is not due to report its primary result until November 29, 2029. [4]
Two firsts, then: one product that will save people who would have bled out waiting for a thaw, and one that lowers a number we have very good reason to think matters, with the proof scheduled for three years from now. Both are real. Only one of them is finished.
